Inquiring about the modest growth in product inspection, whether Q3 activity was pulled forward, and overall spending/demand trends.

Shawn Vadala explained that Q2 was lighter due to project timing after a strong Q1, but mid-single-digit growth is expected in Q3 and high single-digit for the full year (mid-single-digit organic). He highlighted innovation, new products, and success in the mid-market segment as drivers. “But as we kind of like go into the second half of the year, I mean, we feel very good. I mean we're probably looking at mid-single-digit growth in the third quarter. And for the full year, we're probably looking at high single-digit growth, which is probably more like a mid-single-digit growth on an organic basis.”

Asking about Q2 price realization vs. guidance, H2 pricing expectations, and if delayed European chemical orders were recaptured.

Shawn Vadala stated Q2 price realization was around 3%, better than the 2.5% original guidance. H2 pricing is expected around 2.5% due to lapping prior year actions, with full-year approaching 3%. Patrick Kaltenbach noted EU chemical results improved in Q2, but a cautious stance remains due to energy cost exposure. “So in the end, our price realization for the quarter was around 3%. So we're very happy with that. So a little bit better than the 2.5% that you were mentioning in terms of our original guidance.”

Seeking details on drivers of lab improvement, customer feedback on the inflection, and expectations for sustained mid-single-digit growth.

Patrick Kaltenbach attributed lab performance to strong go-to-market strategy, local teams, and innovation. He highlighted process analytics, analytical instruments, and pipetting business returning to growth. He expects mid-single-digit growth to continue, with potential upside from China lab acceleration. “We saw the pipette business coming back to growth as well last quarter, which is very promising. So I would say, yes, we're actually quite pleased with the momentum we have in lab moving forward.”

MTD

Mettler Toledo International (MTD) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 31, 2026

Source: earnings call transcript

Executive summary

Mettler-Toledo Q2 FY26 — Strong Organic Growth and Raised Full-Year Outlook

Mettler-Toledo delivered strong Q2 FY26 results, driven by better-than-expected organic sales growth across its portfolio, particularly in China and emerging markets, and effective Spinnaker sales programs. The company raised its full-year guidance for both sales and adjusted EPS, reflecting improved market conditions and confidence in its strategic execution, while acknowledging potential geopolitical risks.

Highlights

Organic sales grew 4% in local currency, exceeding prior guidance of approximately 3%.
Adjusted EPS increased 14% year-over-year to $11.46.
China organic sales grew 9%, stronger than expected.
Emerging markets outside of China grew high single digits, representing approximately 18% of sales.
Adjusted gross margin expanded 90 basis points (excluding FX and acquisitions) to 59.3%.

Concerns

Middle East volatility could impact customer decision-making, though no change in behavior is currently observed.
Product inspection organic sales growth was modest (1%) due to the timing of customer projects, but expected to pick up in H2.
Americas growth was partly offset by timing of food retail and transportation and logistics project activity.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Local Currency Sales Growth	Approximately 4% to 5% high materiality	FY26	High
Full-year 2026 Adjusted EPS	$47.15 to $47.50 high materiality	FY26	High
Full-year 2026 FX Impact on Sales Growth	1% benefit medium materiality	FY26	High
Q3 2026 Local Currency Sales Growth	Approximately 4% medium materiality	Q3 · FY26	High
Q3 2026 Adjusted EPS	$12 to $12.15 high materiality	Q3 · FY26	High
Q3 2026 FX Impact on Sales	Neutral low materiality	Q3 · FY26	High
Full-year 2026 Total Amortization	Approximately $78 million low materiality	FY26	High
Full-year 2026 Purchased Intangible Amortization (pretax)	$28 million low materiality	FY26	High
Full-year 2026 Interest Expense	$67 million low materiality	FY26	High
Full-year 2026 Other Income	Approximately $24 million low materiality	FY26	High
Full-year 2026 Tax Rate (before discrete items)	19% medium materiality	FY26	High
Full-year 2026 Free Cash Flow	Approximately $900 million high materiality	FY26	High
Full-year 2026 Share Repurchases	$875 million high materiality	FY26	High
China Growth	High single digit medium materiality	Q3 FY26 and FY26	High
Lab Growth	Mid-single digit medium materiality	Q3 · FY26	High
Core Industrial Growth	Low single digit medium materiality	Q3 · FY26	High
Product Inspection Growth	Mid-single digit medium materiality	Q3 · FY26	High
Food Retail Growth	Flat low materiality	Q3 · FY26	High
Americas Growth	Low to mid-single digit medium materiality	Q3 · FY26	High
Europe Growth	Low single digit medium materiality	Q3 · FY26	High
Full-year Lab Growth	Low to mid-single digit medium materiality	FY26	High
Full-year Core Industrial Growth	Low to mid-single digit medium materiality	FY26	High
Full-year Product Inspection Growth	High single digit medium materiality	FY26	High
Full-year Retail Growth	Low to mid-single digit low materiality	FY26	High
Full-year Americas Growth	Low single digit medium materiality	FY26	High
Full-year Europe Growth	Low single digit medium materiality	FY26	High
Full-year China Growth	High single digit medium materiality	FY26	High
H2 2026 Price Realization	2.5% range medium materiality	H2 FY26	High
Full-year 2026 Price Realization	Approaching 3% medium materiality	FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Company Total Exceeded prior guidance of approximately 3% local currency sales growth. Local currency growth: 6%Organic local currency growth: 4%Acquisitions contribution to sales growth: 1.5%	$1 billion	7% USD	—	—
Americas Strong momentum in most lab product categories, core industrial automation solutions, and product inspection, offset by timing of food retail and transportation and logistics project activity.	—	1% organic	—	—
Europe Solid growth across most of the business, including strong growth in core industrial and food retail.	—	4% organic	—	—
Asia/Rest of World Very good growth across the portfolio and in most major markets.	—	9% organic	—	—
China Stronger than expected, led by industrial with double-digit growth, benefiting from biopharma, food, and battery investments. Lab growth was more modest.	—	9% organic	—	—
Emerging Markets (ex-China) Grew high single digits on average in local currencies over the last 5 years, above the company average. Sales as % of total: Approximately 18%	—	High single digits	—	—
Laboratory Good growth across most product areas, improving trends in biopharma, strong growth in process analytics and bioproduction. Analytical instruments and balances growth was strong.	—	4% organic	—	—
Industrial	—	3% organic	—	—
Core Industrial Did well with sales growth driven by strong demand for automation solutions, seeing strength across biopharma, food manufacturing, semiconductor, and new energy.	—	4% organic	—	—
Product Inspection Modest organic sales growth due to timing of customer projects, but expected to pick up in the second half. 70% of business is food manufacturing.	—	1% organic	—	—
Food Retail Better than expected due to the timing of project activity.	—	11% organic	—	—
Service Growing faster than products, exceeded $1 billion in revenues last year. Benefits from AI-supported knowledge base for service engineers.	—	9% reported, 7% organic	—	—

Product announcements

Product	Type	Timeline
New semiautomatic pipette	launch	FY26
New AutoChem solution	launch	FY26
New products in lab product categories	launch	Last few years
New Product Inspection products	launch	FY26

Risks & headwinds

Middle East volatility impacting customer decision-making Ongoing

Not quantified, but could impact customer decision-making should conditions significantly change.

Mitigation:Not included in forecast; company remains agile and focused on execution.

Challenging prior-year comparisons for Q3 Q3 FY26

Core industrial grew 10% organically in Q3 last year; Americas was up 9% organically in Q3 last year.

Mitigation:Management feels good about momentum and guidance despite challenging comps.

Energy cost fluctuations in EU chemical segment Ongoing

Not quantified, but leads to a 'more cautious stance' on the overall segment.

Mitigation:Will have easier comps in quarters to come.

What to watch in Q3 FY26

China Lab Business Acceleration

Second half of the year

Current Modest growth in Q2, industrial-led

Target Pick up in H2, especially from biopharma and academia

Why it matters

Indicates broader recovery in a key growth market beyond industrial and confirms the effectiveness of strategic initiatives.

For lab, the growth was a bit more modest. We expect continued improvement there also in the second half, both also from biopharma and maybe also academia will pick up towards the end of the year.

Find out whether MTD delivers this. Inve re-checks your case every morning.

Q&A highlights

Seeking details on the drivers of China's 9% growth, particularly the mix between industrial/non-pharma and lab/pharma, and expectations for sustained momentum.

Patrick Kaltenbach stated China's growth was led by industrial (double-digit growth), benefiting from biopharma, food, and hot segments like battery investments. Lab growth was more modest but expected to improve in H2, with potential for academia funding. Shawn Vadala confirmed high single-digit growth expected for China in Q3 and full year, with good momentum from automation/digitalization.

“the growth has really been led by industrial, which had double-digit growth in China. We are benefiting from many of the core segments such as biopharma, but also food as well as the hot segments like investments in battery that is happening in China.”

asked by Dan Arias · answered by Patrick Kaltenbach

2 min read 7 chapters

Detailed narrative

Q2 Performance Highlights

Mettler-Toledo reported strong Q2 results with 4% organic sales growth in local currency, surpassing prior guidance of approximately 3%. This performance was driven by improved market conditions, particularly in China and emerging markets, and effective execution of the Spinnaker sales and marketing program. The company also achieved excellent adjusted EPS growth of 14% year-over-year, reaching $11.46.

Geographic Strength and Emerging Markets

Asia/Rest of World demonstrated very strong performance with 9% organic growth, including China, which also grew 9% and exceeded expectations. Emerging markets outside of China, representing approximately 18% of total sales, grew high single digits. Europe delivered solid growth of 4% organically, while Americas grew 1% organically, partially offset by project timing in food retail and transportation and logistics.

Product Area Performance

Laboratory sales increased 4% organically, benefiting from recent innovations and strong demand in biopharma, semiconductor, advanced materials, and battery segments. Core industrial grew 4% organically, driven by automation solutions. Product inspection organic sales growth was modest at 1% due to project timing but is expected to accelerate in the second half. Food retail sales grew 11% due to project activity timing.

Margin Expansion and Profitability

Adjusted gross margin expanded 90 basis points to 59.3% in Q2, excluding the impact of foreign currency and acquisitions. This expansion was primarily driven by favorable price realization, lower tariff rates compared to the prior year, volume growth, and productivity initiatives, partially offset by higher transportation costs. Adjusted operating margin increased 100 basis points, excluding currency, to 29.3%.

Strategic Focus and Outlook

The company remains optimistic about gradual market improvement and is focused on capitalizing on global trends in automation, digitalization, and onshoring investments. Management expressed confidence in continued solid financial performance through strong execution of strategic initiatives, leveraging its sophisticated Spinnaker program, and an innovative product portfolio, positioning the company well regardless of the macro environment.

Innovation and Digitalization Initiatives

Mettler-Toledo's investments in innovation, such as the LabX software platform and AI-supported knowledge bases for service engineers, are driving growth and enhancing customer loyalty. These digital tools provide unique real-time business insights, enabling agile targeting of opportunities in hot segments like bioprocessing, GLP-1s, semiconductor, and battery, and improving service efficiency and first-fixed ratios.

Impact of Pharmacopoeia Revisions

Recent revisions to the U.S., Japanese, and China Pharmacopoeia regarding weighing regulations are driving incremental growth for the company. Mettler-Toledo is well-positioned with its recently launched portfolio of new lab balances to help customers comply with these updated regulations, contributing to the positive momentum in the lab business.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.